Charles River Laboratories International Inc Stock Falls 3.44% to $149.17

Shares of Charles River Laboratories International Inc (CRL) fell 3.44% on July 21, reaching an intraday low of $146.26. Trading volume was 474,812 shares, 60.0% of the average daily volume. Analysts forecast an average target price of $158.53, indicating a 6.28% upside from the current price. The estimated GF Value for CRL in one year is $203.26, suggesting a 36.27% upside.

Title: Charles River Laboratories International Inc (CRL) Stock Falls 3.44% on July 21, 2025

Shares of Charles River Laboratories International Inc (CRL) experienced a significant drop on July 21, 2025, falling by 3.44% and reaching an intraday low of $146.26. Trading volume for the day was 474,812 shares, representing 60.0% of the average daily volume. Analysts forecast an average target price of $158.53, indicating a potential 6.28% upside from the current price. The estimated GF Value for CRL in one year is $203.26, suggesting a 36.27% upside.

The decline in CRL's stock price follows a period of mixed performance. According to the latest earnings reports, the company is expected to report an adjusted EPS of $2.50 for the fiscal Q2 2025, down 10.7% from the year-ago quarter [2]. Despite this, analysts remain cautiously optimistic, with a "Moderate Buy" rating overall and a consensus price target of $162.93 [2].

Oakmark Equity and Income Fund, which holds CRL in its portfolio, reported a one-month return of 8.96% for CRL, but the stock has lost 30.47% of its value over the last 52 weeks [3]. The fund's performance in the second quarter of 2025 was underwhelming, with the equity portfolio returning 4.67% compared to the S&P 500 Index's 10.94% return [3].

Technical analysis of CRL's stock suggests a more negative outlook. The stock holds sell signals from both short and long-term Moving Averages, with resistance at $155.40 and $150.54 [4]. The MACD also indicates a sell signal, and volume rose on falling prices, which may signal further declines [4].

Despite these challenges, CRL's stock has been recognized for its potential in the medical research and drug discovery sectors. The company's services through its Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions segments are essential for pharmaceutical and biotechnology clients [2].

References
[1] https://ir.criver.com/stock-information/historical-price-lookup
[2] https://www.barchart.com/story/news/33491891/here-s-what-to-expect-from-charles-river-laboratories-next-earnings-report
[3] https://finance.yahoo.com/news/charles-river-laboratories-international-crl-135135604.html
[4] https://stockinvest.us/stock/CRL